FIRST AMENDMENT TO LICENSE AND COLLABORATION AGREEMENT (PNT-2002)License and Collaboration Agreement • May 2nd, 2024 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • Delaware
This First Amendment to License and Collaboration Agreement (this “Amendment”) is entered into as of January 31, 2024, by and between POINT Biopharma, Inc., a Delaware corporation (“POINT”), and Lantheus Two, LLC, a Delaware limited liability company (“Lantheus”) and Lantheus Medical Imaging, Inc., a Delaware corporation (“LMI” and together with POINT and Lantheus, the “Parties” and each, a “Party”), and amends that certain License and Collaboration Agreement (PNT-2002), dated November 11, 2022, by and among the Parties (the “Agreement”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement.
